1685 completed, 314 unknown, 261 recruiting, 111 terminated. 1717 Not applicable, 227 Phase 2, 150 Phase 3, 121 Phase 4, 98 Phase 1.
Follow Body Weight Changes: new trials by email Literature Review of Body Weight Changes trials Research Report on Body Weight Changes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Learning Early Infant Feeding Cues Learning Early Infant Feeding Cues - Responsive Feeding, Infants | Not applicable | Not yet recruiting | Florida State University | 39 | 2027-07-01 | 2026-04-27 |
| Simplifying Diet Tracking in a Digital Weight Loss Intervention Simplified Dietary Self-Monitoring, Detailed Dietary Self-Monitoring, Core Behavioral Weight Loss Intervention - Overweight, Obesity | Not applicable | Not yet recruiting | Stanford University | 328 | 2027-05-01 | 2026-05-28 |
| Optimization of Dietary Adherence in a Mobile Weight Loss Intervention Core, Switch to Simplified Diet Monitoring, Goal Autonomy/Planning - Overweight and/or Obesity | Not applicable | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 580 | 2027-03-01 | 2026-05-15 |
| Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer Semaglutide (Wegovy®) - Breast Cancer (Early Breast Cancer), Obesity | Phase 2 | Not yet recruiting | Aarhus University Hospital | 32 | 2027-03-01 | 2026-11-02 |
| Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity Semaglutide - Pediatric Obesity, Obesity | Not yet recruiting | Erin Mauney | 12 | 2027-03-01 | 2026-11-02 | |
| Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes Supervised exercise training, protein supplement, Standardized lifestyle counseling - Type 2 Diabetes (T2DM), Obesity & Overweight | Not applicable | Not yet recruiting | German Diabetes Center | 94 | 2027-02-01 | 2026-11-09 |
| Addressing Food Access and Physical Activity to Improve Diabetes Prevention Outcomes Among Underserved African Americans Culturally-tailored, enhanced adaption of Diabetes Prevention Program - Diabetes, Physical Activity | Not applicable | Not yet recruiting | University of Missouri, Kansas City | 408 | 2027-01-04 | 2026-06-09 |
| Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer Semaglutide (Wegovy) weekly injection, LNG-IUD (Progestin), Structured Weight Loss Program - Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia | Phase 2 | Not yet recruiting | The Methodist Hospital Research Institute | 48 | 2027-01-01 | 2026-10-01 |
| Study Evaluating the Metabolic Effects of pulsENDO Therapy in Adults With Type 2 Diabetes pulsENDO Therapy - Diabetes Type 2, Diabetes | Not applicable | Not yet recruiting | Endogenex, Inc. | 320 | 2027-01-01 | 2026-08-18 |
| Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD) Endothelial cell collection - Obesity and Obesity-related Medical Conditions, Diabetes | Recruiting | Bettina Mittendorfer | 100 | 2027-01-01 | 2026-05-07 | |
| Diabetes Prevention Through Genetics, Familial History and Behavior Change LEGACY DPP, DPP - Prediabetes, Weight Loss | Phase 2 / Phase 3 | Not yet recruiting | Morehouse School of Medicine | 400 | 2027-01-01 | 2026-10-20 |
| A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia SXRN Injection, Placebo - Cachexia-Anorexia Syndrome, Cachexia; Cancer | Phase 2 | Not yet recruiting | Jiangsu Guiqiong Pharmaceutical Co., Ltd. | 96 | 2026-12-01 | 2026-10-26 |
| Weight Changes After Incretin-mimetics discontinuation of weight loss medication - Obesity and Obesity-related Medical Conditions | Not applicable | Not yet recruiting | Medical College of Wisconsin | 52 | 2026-12-01 | 2026-02-24 |
| Weight Loss Composition and Metabolic Adaptation During Hypocaloric Dieting Hypocaloric Diet - Obesity | Not applicable | Not yet recruiting | Tel Aviv University | 150 | 2026-12-01 | 2026-10-08 |
| Gut-Liver-Muscle Axis in Cancer Cachexia Impact Advanced Recovery (Impact AR), Boost® High Protein + Beneprotein® - Head & Neck Cancer | Not applicable | Not yet recruiting | University of Colorado, Denver | 20 | 2026-12-01 | 2026-11-05 |
| Phase 1/2 Study of DS010 in Advanced Cancer Patients With Cachexia DS010 injection - Cancer, Cachexia | Phase 1 / Phase 2 | Recruiting | Dartsbio Pharmaceuticals Ltd. | 58 | 2026-11-30 | 2026-11-06 |
| Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity Liver-expressed antimicrobial peptide 2, Placebo - Obesity & Overweight | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Gentofte, Copenhagen | 18 | 2026-11-30 | 2026-10-27 |
| Effect of Earmuffs on Physiological Stability, Sleep-Wake States, and Weight Gain in Preterm Neonates Neonatal Earmuffs - Preterm Infants | Not applicable | Not yet recruiting | University of Baghdad | 80 | 2026-11-20 | 2026-11-12 |
| The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight Berobenatide, Placebo - Urinary Incontinence, Stress, Overweight and/or Obesity | Phase 3 | Not yet recruiting | Pfizer | 900 | 2026-11-17 | 2026-11-12 |
| Building Opportunities for Nurturing Care to Enhance Child Development in Eastern and Southern Africa Friendship Bench, Infant and Young Child Feeding (IYCF) Curriculum, Play-Based Curriculum - Neurodevelopment, Child Growth | Not applicable | Not yet recruiting | University of Washington | 1260 | 2026-11-01 | 2026-03-03 |
Showing 20 of 2663. Sign in to see all of them.
Weight Loss (1806) · Obesity (1296) · Overweight (477) · Cachexia (303) · Weight Gain (303) · Motor Activity (291) · Gestational Weight Gain (134) · Body Weight (111) · Diabetes Mellitus, Type 2 (109) · Neoplasms (103) · Diabetes Mellitus (101) · Metabolic Syndrome (100) · Obesity, Morbid (92) · Insulin Resistance (86)
Pathological Conditions, Signs and Symptoms (2663) · Signs and Symptoms (2658) · Body Weight (2552) · Nutritional and Metabolic Diseases (1713) · Nutrition Disorders (1526) · Overnutrition (1423) · Overweight (953) · Behavior (522) · Metabolic Diseases (447) · Glucose Metabolism Disorders (385) · Endocrine System Diseases (322) · Thinness (290) · Weight Loss (277) · Neoplasms by Site (192)
Exercise (102) · Diet (61) · Caloric Restriction (49) · semaglutide (30) · Standard of Care (28) · Nutrition Assessment (26) · Diet Therapy (23) · Gastric Bypass (23) · Metformin (23) · Control Groups (22) · Bariatric Surgery (21) · Behavior Therapy (20) · Counseling (19) · Liraglutide (18) · Megestrol Acetate (18)
Wake Forest University Health Sciences (40) · The Miriam Hospital (31) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (29) · University of Alabama at Birmingham (27) · University of Colorado, Denver (27) · Pennington Biomedical Research Center (26) · University of North Carolina, Chapel Hill (25) · University of Pittsburgh (25) · University of Pennsylvania (24) · University of Kansas Medical Center (23) · Duke University (22) · University of California, San Diego (22) · VA Office of Research and Development (22) · Washington University School of Medicine (22) · Stanford University (21)
United States (1312) · Canada (106) · China (89) · United Kingdom (83) · Germany (79) · Spain (69) · Denmark (67) · Italy (57) · France (53) · Turkey (Türkiye) (51) · Brazil (38) · Norway (36) · Sweden (36) · Netherlands (34) · Taiwan (34)
Samuel Klein, MD (9) · David Crowley, MD (5) · Holly Wyatt, MD (5) · Jack A Yanovski, M.D. (5) · James Hill, PhD (5) · Jessica G LaRose, PhD (5) · John M Jakicic, Ph.D. (5) · Aminah Jatoi, MD (4) · Cheryl L Rock, PhD, RD (4) · David S Ludwig, MD, PhD (4) · Deborah F. Tate, PhD (4) · Hamid R Farshchi, MD, PhD (4)
PMID 33512717, PMID 38375882, PMID 26708836, PMID 30230252, PMID 33238176, PMID 40839263, PMID 41029405, PMID 23661689, PMID 27206567, PMID 27659698, PMID 27888609, PMID 28472437, PMID 30651576, PMID 32002540, PMID 34544560, PMID 35538903, PMID 37652841, PMID 40705619, PMID 18753666, PMID 20145731, PMID 20222968, PMID 22085317, PMID 22127229, PMID 22513296, PMID 23229890, PMID 23364004, PMID 24081232, PMID 24500151, PMID 24670075, PMID 25475207, PMID 25972230, PMID 26395743, PMID 26641646, PMID 26906526, PMID 27116910, PMID 27676466, PMID 28494136, PMID 29777235, PMID 30475957, PMID 31004409, PMID 31012296, PMID 31155473, PMID 31409509, PMID 32118268, PMID 32651241, PMID 33240920, PMID 33344496, PMID 33677781, PMID 33789551, PMID 34611902
P50MD017338 (4), R01AG012161 (4), 2018 (3), 2023 (3), P20GM144269 (3), R01HL140574 (3), U10CA081920 (3), 2016 (2), 2017 (2), 8UL1GM118979-02 (2), K01HL141535 (2), K23AG051681 (2), K24DK065018 (2), P20NR011404 (2), P30CA043703 (2)